IS7999A - Prostaglandín hliðstæður sem EP4 viðtaka mótlyf - Google Patents

Prostaglandín hliðstæður sem EP4 viðtaka mótlyf

Info

Publication number
IS7999A
IS7999A IS7999A IS7999A IS7999A IS 7999 A IS7999 A IS 7999A IS 7999 A IS7999 A IS 7999A IS 7999 A IS7999 A IS 7999A IS 7999 A IS7999 A IS 7999A
Authority
IS
Iceland
Prior art keywords
receptor antagonist
prostaglandin analogues
prostaglandin
analogues
antagonist
Prior art date
Application number
IS7999A
Other languages
English (en)
Inventor
Billot Xavier
Colucci John
Han Yongxin
Wilson Marie-Claire
N. Young Robert
Original Assignee
Merck Frosst Canada Ltd.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Frosst Canada Ltd. filed Critical Merck Frosst Canada Ltd.
Publication of IS7999A publication Critical patent/IS7999A/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02—Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A61P19/10—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease for osteoporosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
    • A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D211/00—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings
    • C07D211/04—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D211/68—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member
    • C07D211/72—Heterocyclic compounds containing hydrogenated pyridine rings, not condensed with other rings with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms, with at the most one bond to halogen, directly attached to ring carbon atoms
    • C07D211/74—Oxygen atoms
    • C07D211/76—Oxygen atoms attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D265/00—Heterocyclic compounds containing six-membered rings having one nitrogen atom and one oxygen atom as the only ring hetero atoms
    • C07D265/04—1,3-Oxazines; Hydrogenated 1,3-oxazines
    • C07D265/06—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings
    • C07D265/08—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D265/10—1,3-Oxazines; Hydrogenated 1,3-oxazines not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with oxygen atoms directly attached to ring carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Ophthalmology & Optometry (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Cardiology (AREA)
  • Obesity (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Oncology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Hydrogenated Pyridines (AREA)
IS7999A 2003-03-26 2005-08-25 Prostaglandín hliðstæður sem EP4 viðtaka mótlyf IS7999A (is)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US45770003P 2003-03-26 2003-03-26
PCT/CA2004/000471 WO2004085431A1 (en) 2003-03-26 2004-03-26 Prostaglandin analogs as ep4 receptor antagonists

Publications (1)

Publication Number Publication Date
IS7999A true IS7999A (is) 2005-08-25

Family

ID=33098243

Family Applications (1)

Application Number Title Priority Date Filing Date
IS7999A IS7999A (is) 2003-03-26 2005-08-25 Prostaglandín hliðstæður sem EP4 viðtaka mótlyf

Country Status (22)

Country Link
US (4) US7053085B2 (is)
EP (1) EP1613621B1 (is)
JP (1) JP4866992B2 (is)
KR (1) KR20060002873A (is)
CN (1) CN1764659A (is)
AR (1) AR040806A1 (is)
AT (1) ATE474837T1 (is)
BR (1) BRPI0408690A (is)
CA (1) CA2519938C (is)
CL (1) CL2004000655A1 (is)
DE (1) DE602004028229D1 (is)
EC (1) ECSP056037A (is)
ES (1) ES2347434T3 (is)
HR (1) HRP20050845A2 (is)
IS (1) IS7999A (is)
MA (1) MA27667A1 (is)
MX (1) MXPA05010189A (is)
NO (1) NO20054951L (is)
PE (1) PE20050522A1 (is)
RU (1) RU2005132930A (is)
TW (1) TW200427670A (is)
WO (2) WO2004085431A1 (is)

Families Citing this family (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BRPI0406717A (pt) * 2003-01-10 2005-12-20 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
JP2006527189A (ja) * 2003-06-06 2006-11-30 アラーガン、インコーポレイテッド ピペリジニルプロスタグランジンｅ類似体
US7326716B2 (en) 2003-06-06 2008-02-05 Allergan, Inc. Treatment of inflammatory bowel disease
US6977260B2 (en) 2004-01-22 2005-12-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
US7179820B2 (en) * 2003-06-06 2007-02-20 Allergan, Inc. Piperidinyl prostaglandin E analogs
CN1845914A (zh) 2003-09-02 2006-10-11 默克公司 用于治疗眼压过高的眼用组合物
AU2004272546B2 (en) 2003-09-04 2007-10-18 Merck Sharp & Dohme Corp. Ophthalmic compositions for treating ocular hypertension
AU2004271978B2 (en) 2003-09-04 2009-02-05 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
US7427614B2 (en) 2004-07-02 2008-09-23 Allergan, Inc. Prostaglandin analogs
CN1988903A (zh) * 2004-07-20 2007-06-27 默克公司 用于治疗高眼压症的眼用组合物
JP2008518013A (ja) * 2004-10-26 2008-05-29 アラーガン、インコーポレイテッド プロスタグランジンｅｐ４アゴニストによる処置方法およびデリバリー方法
WO2006052630A1 (en) * 2004-11-04 2006-05-18 Allergan, Inc. Therapeutic substituted piperidone compounds
US7531533B2 (en) 2005-01-27 2009-05-12 Asahi Kasei Pharma Corporation 6-Membered heterocyclic compound and use thereof
KR100890490B1 (ko) * 2005-01-27 2009-03-26 아사히 가세이 파마 가부시키가이샤 헤테로 6원환 화합물 및 그의 용도
AU2006275263A1 (en) * 2005-08-03 2007-02-08 Merck Frosst Canada Ltd EP4 receptor agonist, compositions and methods thereof
EP1912977A4 (en) * 2005-08-03 2009-10-21 Merck Frosst Canada Ltd EP4 RECEPTOR AGONIST, COMPOSITIONS AND METHODS
UY30121A1 (es) 2006-02-03 2007-08-31 Glaxo Group Ltd Nuevos compuestos
US7498447B2 (en) 2006-05-24 2009-03-03 Allergan, Inc. Therapeutic compounds
US7550448B2 (en) 2006-05-24 2009-06-23 Allergan, Inc. Therapeutic compounds
WO2008027340A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
WO2008027341A2 (en) * 2006-08-30 2008-03-06 Merck & Co., Inc. Topical ophthalmic formulations
EP3824885A1 (en) 2006-10-20 2021-05-26 Children's Medical Center Corporation Method to enhance tissue regeneration
CN101168514B (zh) * 2006-10-26 2011-12-07 上海药明康德新药开发有限公司 光学活性α-氨基辛二酸酯和α-氨基辛二酸单酯的合成方法
NZ577109A (en) 2006-12-15 2011-12-22 Glaxo Group Ltd Benzamide derivatives as ep4 receptor agonists
GB2446652A (en) * 2007-02-16 2008-08-20 Inion Ltd Osteogenic compounds
AU2008246579A1 (en) 2007-05-08 2008-11-13 National University Corporation, Hamamatsu University School Of Medicine Cytotoxic T cell activator comprising EP4 agonist
EP2154130A4 (en) * 2007-06-07 2011-09-07 Astellas Pharma Inc pyridone
GB0721611D0 (en) 2007-11-02 2007-12-12 Glaxo Group Ltd Novel compounds
CN101468985A (zh) * 2007-12-28 2009-07-01 中国人民解放军军事医学科学院毒物药物研究所 5-(3-芳杂环取代苯基)四氮唑类化合物及其抗hiv/aids的应用
US8633310B2 (en) * 2008-02-19 2014-01-21 Allergan, Inc. Therapeutic substituted lactams
US7964596B2 (en) 2008-03-07 2011-06-21 Allergan, Inc. Therapeutic compounds
KR20120093955A (ko) 2009-10-14 2012-08-23 젬머스 파마 인코포레이티드 바이러스 감염에 대한 병용 요법 치료
CA2738045C (en) 2010-05-28 2019-02-19 Simon Fraser University Conjugate compounds, methods of making same, and uses thereof
KR20160042039A (ko) 2013-08-09 2016-04-18 알데릭스, 인코포레이티드 인산염 수송을 억제하기 위한 화합물 및 방법
US9650414B1 (en) 2014-05-30 2017-05-16 Simon Fraser University Dual-action EP4 agonist—bisphosphonate conjugates and uses thereof
US10400000B2 (en) 2015-06-12 2019-09-03 Simon Fraser University Amide-linked EP4 agonist-bisphosphonate compounds and uses thereof
WO2017126635A1 (ja) * 2016-01-22 2017-07-27 武田薬品工業株式会社 複素環化合物およびその用途
US10988468B2 (en) 2017-12-25 2021-04-27 Asahi Kasei Pharma Corporation Nitrogen-containing 6-membered cyclic compound
WO2020237096A1 (en) 2019-05-21 2020-11-26 Ardelyx, Inc. Combination for lowering serum phosphate in a patient
CN111269193B (zh) * 2020-04-02 2022-05-24 湖南海利常德农药化工有限公司 一种苯并[e][1,3]噁嗪-2,4-二酮的制备方法

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1524818A (en) 1974-11-29 1978-09-13 Beecham Group Ltd 12-azaprostaglandins
US4177346A (en) 1976-08-06 1979-12-04 Pfizer Inc. 1,5-Disubstituted-2-pyrrolidones
EP0008186A1 (en) 1978-08-08 1980-02-20 Beecham Group Plc Cyclic diamides, a process for their preparation and their pharmaceutical compositions
FR2534580A1 (fr) 1982-10-13 1984-04-20 Synthelabo Derives de phenyl-1 piperidino-2 propanol, leur preparation, et medicaments qui les contiennent
US5151444B1 (en) 1987-09-18 1999-07-06 R Tech Ueno Ltd Ocular hypotensive agents
US4960771A (en) * 1988-07-12 1990-10-02 Rajadhyaksha Vithal J Oxazolidinone penetration enhancing compounds
US5296504A (en) 1988-09-06 1994-03-22 Kabi Pharmacia Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
EP1348437A3 (en) 1988-09-06 2003-11-19 Pharmacia Aktiebolag Prostaglandin derivatives for the treatment of glaucoma or ocular hypertension
US5352708A (en) 1992-09-21 1994-10-04 Allergan, Inc. Non-acidic cyclopentane heptanoic acid, 2-cycloalkyl or arylalkyl derivatives as therapeutic agents
US5922773A (en) 1992-12-04 1999-07-13 The Children's Medical Center Corp. Glaucoma treatment
US5510383A (en) 1993-08-03 1996-04-23 Alcon Laboratories, Inc. Use of cloprostenol, fluprostenol and their salts and esters to treat glaucoma and ocular hypertension
JPH10265454A (ja) 1997-01-27 1998-10-06 Ono Pharmaceut Co Ltd ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
US6043275A (en) 1998-04-16 2000-03-28 Ono Pharmaceutical Co., Ltd. 3,7-dithiaprostanoic acid derivative
KR20010074981A (ko) 1998-09-14 2001-08-09 우에노 도시오 ω치환된 페닐프로스타그란딘 Ｅ 유도체 및 그 유도체를유효 성분으로 하는 약제
AU6427599A (en) 1998-10-15 2000-05-01 Merck & Co., Inc. Methods for stimulating bone formation
AU2183900A (en) 1998-12-24 2000-07-31 Alcon Laboratories, Inc. Ep4 receptor agonists for treatment of dry eye
PL356662A1 (en) 1999-12-22 2004-06-28 Pfizer Products Inc. Ep4 receptor selective agonists in the treatment of osteoporosis
PL358481A1 (en) 2000-03-17 2004-08-09 Alcon Inc. 6-hydroxy-indazole derivatives for treating glaucoma
AU4466901A (en) 2000-03-31 2001-10-08 Toray Industries, Inc. Hair growth or hair formation controlling agents
AU2001290250A1 (en) 2000-09-21 2002-04-02 Ono Pharmaceutical Co. Ltd. Ep4 receptor agonists containing 8-azaprostaglandin derivatives as the active ingredient
NZ525164A (en) 2000-11-27 2005-04-29 Pfizer Prod Inc EP4 receptor selective agonists in the treatment of osteoporosis
JP2004530647A (ja) 2001-01-30 2004-10-07 メルク　エンド　カムパニー　インコーポレーテッド 高眼圧治療用眼薬組成物
CA2441708A1 (en) 2001-03-22 2002-10-03 Merck & Co., Inc. Mch1r deficient mice
CA2466751A1 (en) 2001-12-03 2003-06-12 Merck And Co., Inc. Ep4 receptor agonist, compositions and methods thereof
EP1461026A2 (en) 2001-12-03 2004-09-29 Merck & Co., Inc. Method for treating ocular hypertension
CA2488802A1 (en) 2002-06-14 2003-12-24 Merck & Co., Inc. Ophthalmic compositions for treating ocular hypertension
JP2005533055A (ja) 2002-06-17 2005-11-04 メルク　エンド　カムパニー　インコーポレーテッド 新規マキシｋチャンネルブロッカー、その使用方法および製造方法
CA2488884A1 (en) 2002-06-17 2003-12-24 Merck & Co., Inc. Novel maxi-k channel blockers, methods of use and process for making the same
US7053085B2 (en) * 2003-03-26 2006-05-30 Merck & Co. Inc. EP4 receptor agonist, compositions and methods thereof
BRPI0406717A (pt) * 2003-01-10 2005-12-20 Hoffmann La Roche Composto, composição farmacêutica que compreende o mesmo, método de tratamento de uma enfermidade em um mamìfero, utilização do composto e processo para a sua produção
US6747037B1 (en) 2003-06-06 2004-06-08 Allergan, Inc. Piperidinyl prostaglandin E analogs

Also Published As

Publication number Publication date
NO20054951L (no) 2005-12-22
KR20060002873A (ko) 2006-01-09
US20110237511A1 (en) 2011-09-29
MXPA05010189A (es) 2006-02-22
AU2004224261A1 (en) 2004-10-07
NO20054951D0 (no) 2005-10-25
US7053085B2 (en) 2006-05-30
ES2347434T3 (es) 2010-10-29
WO2004085431A1 (en) 2004-10-07
CA2519938A1 (en) 2004-10-07
US20050227969A1 (en) 2005-10-13
AR040806A1 (es) 2005-04-20
BRPI0408690A (pt) 2006-03-28
CL2004000655A1 (es) 2005-01-21
CN1764659A (zh) 2006-04-26
MA27667A1 (fr) 2005-12-01
EP1613621B1 (en) 2010-07-21
TW200427670A (en) 2004-12-16
JP2006520758A (ja) 2006-09-14
HRP20050845A2 (en) 2006-05-31
USRE42562E1 (en) 2011-07-19
RU2005132930A (ru) 2006-02-10
EP1613621A1 (en) 2006-01-11
JP4866992B2 (ja) 2012-02-01
PE20050522A1 (es) 2005-07-06
DE602004028229D1 (de) 2010-09-02
ATE474837T1 (de) 2010-08-15
WO2004085430A1 (en) 2004-10-07
US7238710B2 (en) 2007-07-03
ECSP056037A (es) 2006-01-27
CA2519938C (en) 2010-11-30
US20040198701A1 (en) 2004-10-07

Similar Documents

Publication Publication Date Title
NO20054951D0 (no) Prostaglandinanaloger som EP4-reseptorantagonister
CY2013035I1 (el) Μεθοδοι χρησης συνθεσεων αμινοπυριδινης παρατεταμενης αποδεσμευσης
IS8199A (is) Afleiður (þíó) karbamóýl-sýklóhexans sem mótlyf D3/D2 viðtaka
IS8501A (is) Azatvíhringja heteróhringir sem kannabínóníð-viðtakastillar
MA28841B1 (fr) Analogues tetrapeptidiques
MA28857B1 (fr) Analogues de pipérazinyl-pyridine biaryliques substitués
IS8345A (is) 6-útskipt anilínópúrín sem RTK-tálmar
IL184816A0 (en) 2-phenyl-indoles as prostaglandin d2 receptor antagonists
IS2756B (is) Samrunnin heteróhringssambönd sem stillar fyrir viðtaka serótóníns
IL182090A0 (en) 2,6-substituted-4-monosubstitutedamino-pyrimidine as prostaglandin d2 receptor antagonists
DK1501809T3 (da) Trizolderivater som tachykininreceptorantagonister
DK1660090T3 (da) Quinazolin-analoger som receptor-tyrosinkinase-inhibitorer
DE602005004011D1 (de) Hydroisoindolin-tachykininrezeptorantagonisten
NO20054669D0 (no) Substituerte kinobenzoxazinanaloger
DK1776090T3 (da) Stabiliseret prostaglandinsammensætning
DK1648882T3 (da) 3-fluor-piperidiner som NMDA/NR2B-antagonister
IS2456B (is) Ímídasókínólínafleiður sem adenósín A3 viðtakabindlar
IS8291A (is) Pýrról-2,5-tvíþíónafleiður sem lifrar X viðtakastillar
AP2006003840A0 (en) Indole-2-carboxamidine derivatives as NMDA receptor antagonists
ATE406366T1 (de) Gehinderte himbacinanaloga als thrombinrezeptorantagonisten
DE602005001661D1 (de) Vermessungsgerät
EP1888618A4 (en) Analogs of glycyl-prolyl-glutamate
IS8278A (is) Sýkóprópýl afleiður sem NK3 viðtaka mótlyf
EP1898905A4 (en) HYDROISOINDOLIN-tachykinin receptor Antagonist
IS7452A (is) Prógesterón viðtakastillar sem ekki eru steratengdir